This is open-label, multi-center, non-comparative, non-interventional observational study to assess safety and effectiveness of Pluvicto in patients with mCRPC in the real-world setting in South Korea.
Age
18–100
Sex
MALE
Healthy volunteers
Not accepted
You may be eligible if
Study participants eligible for inclusion in this study must meet all of the following criteria:
1. Male adult patient age ≥ 18
2. Subject who are being treated with Pluvicto or whose treatment plan is finalized and scheduled to be administered at the time of consent by physician in accordance with the approved indication in South Korea
3. Subject who provided the written informed consent prior to the study enrollment
You may not be if
1. Subject whose medical record is not accessible
2. Subject who is not willing to provide the informed consent
Clareo Health | Post Marketing Study on Pluvicto in Korea
